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A B S T R A C T
In immunocompromised patients, Fusarium species cause infections that lead to high mortality. Our case
report describes a case of disseminated fusariosis in a neutropenic patient with AML after
myelosuppressive chemotherapy, and a neutropenic multiple myeloma patient with Fusarium fungemia
awaiting stem cell collection. Both cases highlight the fact that Fusarium can grow as yeast-like
structures in the blood causing a delay in diagnosis, and that Fusarium has a tendency to be a resistant
organism. Fusarium was only susceptible to amphotericin B in both cases, but we chose to continue
treatment with voriconazole in the ﬁrst case with disseminated infection, despite culture results, in view
of his good clinical response. Despite high mortality rates in disseminated infection, our two patients had
good outcomes.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fusarium are ﬁlamentous non-pigmented septated fungi
ubiquitous in the environment. Fusariosis is a not uncommon
invasive mold infection in patients with hematologic malignancies
and hematopoietic cell transplants. Infection tends to spread
rapidly in immunocompromised patients due to angioinvasiveness
and fungemia but tends to remain localized in immunocompetent
patients. Blood cultures are positive in almost half of the
immunocompromised patients with Fusarium infection [1]. Fusar-
iosis has high mortality rate once disseminated, and reversion of
neutropenia is imperative along with antifungal therapy with
voriconazole or amphotericin B.
Case report #1
A 63 year-old-male was admitted to our institution with the
chief complaint of productive cough for 4 days, associated with
fever up to 101.28F, pleuritic chest pain, asthenia and emesis. The
patient had history of acute myeloid leukemia, recently completed
consolidation cycle #3 with high-dose cytarabine for 10 days prior
to this admission, and was taking acyclovir, ﬂuconazole and* Corresponding author at: University of Arkansas for Medical Sciences,
Department of Internal Medicine, Little Rock, AR, USA.
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4.0/).levoﬂoxacin for neutropenic prophylaxis. Past medical history was
also remarkable for diabetes and DVT. He is a retired truck driver,
lives with his wife and has no toxic habits or family history of
malignancies.
Upon examination, the patient appeared ill, afebrile (T 98.78F),
tachycardic (HR 122 bpm), normotensive (BP 120/62 mmHg) and
tachypneic (RR 29 breaths per minute). His physical exam revealed
respiratory distress with clear lung auscultation, and left arm PICC
line with no signs of infection. Skin was intact. Laboratory results
were remarkable for pancytopenia with profound neutropenia
(WBC 0.02), severe anemia (Hgb 5.3), thrombocytopenia (plat 12),
mild acute kidney injury, and elevated blood glucose. Chest X-ray
showed bibasilar atelectasis and small right pleural effusion.
Cefepime and vancomycin intravenously were started empirically
for neutropenic fever. Fluconazole and acyclovir were continued as
prophylaxis.
Chest CT was obtained the following day in view of persistent
fevers and respiratory distress, and revealed bilateral nodular
opacities (Fig. 1). Yeast-like forms were observed on gram stain on
day 2 of incubation of the aerobic blood culture bottle, and the
same bottle on day 4 also showed hyphae (Figs. 2 and 3).
Fluconazole was stopped and amphotericin B 3 mg/kg intrave-
nously daily was started until blood culture revealed Fusarium spp.
four days after presentation to ED. At that time, amphotericin B
was switched to voriconazole IV. Patient was discharged on oral
voriconazole seven days after admission.e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
Fig. 1. CT chest demonstrating multiple rounded nodular densities scattered throughout the both lungs.
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fungal sensitivities showed azole-resistant Fusarium, only sensitive
to amphotericin B. In view of good clinical response, it was decided
to continue voriconazole PO for a total of 6 months. Repeated CT
chest ﬁve months after starting antifungal treatment showed
complete resolution of pulmonary nodules. During treatment
course patient developed nausea and mild transaminitis that did
not require discontinuation of the drug.
Case report #2
The patient in this case was a 46 year-old-male with high risk
multiple myeloma with CNS involvement and heavily treated in
the past who presented to our infusion center on day 13 post-
chemotherapy with fever, chills, odynophagia, dysphagia and
vomiting. He had completed a cycle of chemotherapy with
cisplatin, adriamycin, cyclophosphamide, mesna, etoposide and
dexamethasone. No other comorbidities were reported. Patient
lived with his mother, was a former smoker, and uncle had history
of cancer. He was on levoﬂoxacin, ﬂuconazole and acyclovir as
standard precautions.
At the time of our evaluation, he appeared chronically ill,
afebrile (T 96.78F), tachycardic (HR 95 bpm), normotensive (BP
113/73 mmHg) and normal respiratory rate. His physicalFigs. 2 and 3. Gram stain initially showing spores deexam revealed mild mucositis, and pedal edema. He had an
Ommaya reservoir, an implanted port, and a subclavian
central venous catheter with no signs of infection. No skin
lesions were identiﬁed. Laboratory results were remarkable for
pancytopenia with profound neutropenia (WBC 0.02), anemia
(Hgb 8.6), thrombocytopenia (plat 14), hyponatremia (Na
125 mmol/L), hypophosphatemia (P 1.8 mg/dL) and elevated
CRP (199 mg/L). A PET/CT showed no infection. Cefepime and
vancomycin intravenously were started empirically for neutro-
penic fever, and ﬂuconazole and acyclovir were continued as
prophylaxis.
Four days after a blood culture was obtained from central
venous line, yeast grew in the aerobic bottle. Central venous line
was removed but Iport was kept in view of negativity of repeated
culture studies. Fluconazole was switched for micafungin intrave-
nously until culture revealed Fusarium spp. 8 days after blood
culture collection. Micafungin was stopped, and patient was
started on combination therapy with amphotericin B intravenous-
ly and voriconazole intravenously.
Culture results revealed azole-resistant Fusarium with ampho-
tericin B MIC of 2. Patient received a total of 6 weeks of
amphotericin B for Fusarium fungemia. Infection resolved, but
unfortunately patient died 8 months after the fusariosis due to a
relapse of end-stage, refractory multiple myeloma.scribe as yeast forms, and later septated hyphae.
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Fusarium is the second or third most common invasive mold
infection in immunocompromised patients. It is especially
prevalent in patients with hematologic malignancies and hemato-
poietic cell transplants. A recent study found that smoking was the
only signiﬁcant variable associated with invasive fusariosis in AML
patients [2]. In the immunocompromised host, the principal portal
of entry for Fusarium spp. is the airways, followed by the skin at site
of tissue breakdown and mucosal membranes [1]. In the ﬁrst case,
the most likely portal of entry was the airway, whereas mucosal
membrane due to mucositis would be the most reasonable focus in
the second patient.
Although sometimes similar in the population at risk,
presentation and radiological imaging, aspergillosis and fusariosis
are different in that fusariosis has a much higher rate of blood
culture positivity. In one study looking at 294 patients with
fusariosis, 41% had positive blood cultures yielding Fusarium [1]. In
our report, blood cultures were initially reported with yeast-like
structures, delaying correct treatment in both patients due to
adventitious sporulation in the blood culture bottle. Adventitious
sporulation is the presence of fungal reproductive structures
within infected tissue. Those reproductive structures include,
fertile cells known as phialides, and the conidia (spores) that arise
serially from the apical oriﬁce of each phialide [3]. Schell also
hypothesized that the sustained release of fungal spores into the
bloodstream, via angioinvasion and adventitious sporulation, may
explain the higher prevalence of positive blood culture results and
rapid rate of dissemination associated with fusariosis [3]. Adventi-
tious sporulation in Fusarium spp. was ﬁrst observed by Wolf in
1955, and erroneously described as a phenomenon of dimorphism
by Kidd and Wolf in 1973 in a patient with mycotic keratitis caused
by Fusarium moniliforme [4,5]. They incorrectly thought Fusarium
spp. grew in two different morphological forms depending on the
culture media, distinguishing a mycelial phase on solid and liquid
media, and a yeast phase on liquid media upon agitation at 25 8C
and 37 8C.
Both patients were neutropenic due to myelosuppressive
chemotherapy for their underlying hematological malignancy.
Rapid reversion of neutropenia along with appropriate therapy
with either amphotericin B or voriconazole are key to prevent a
fatal outcome. Posaconazole is considered salvage therapy, and
isavuconazole, a new broad-spectrum triazole, has shown limitedin vitro activity against Fusarium species, with a MIC90of 16 mg/mL
[6]. Removal of infected catheters and surgical debridement of large
single lesions are also recommended. In a study of 84 patients with
fusariosis and hematologic malignancies, only 18 of 84 patients
(21%) survived after 90 days. Of those 66 deaths, 59 died of fusariosis
[7]. Another study showed only 13% of patients with fusariosis and
hematopoietic cell transplants survived after 90 days [8]. Despite
both isolates showed high MIC for voriconazole, the ﬁrst patient was
managed with voriconazole in view of his good clinical response.
Different species may have different patterns of susceptibility. The
relevance of these in vitro data is not clear, because there are not
enough data documenting a correlation between MICs and the
clinical outcome [1]. In one study of 26 patients with a Fusarium
infection, 46% were cured or improved with Amphotericin B lipid
complex [9]. Another retrospective study with 73 patients with
proven or probable Fusarium infection in France showed a 47%
success rate with voriconazole [10]. The optimal duration of therapy
remains unclear due to the lack of trials. We chose to use antifungal
treatment for 6 months in disseminated fusariosis, and 6 weeks in
isolated fungemia.
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